IL-23 Inhibitor for Schizophrenia

This trial explores a new treatment approach for individuals with schizophrenia or schizoaffective disorder who have specific immune markers. It tests whether mirikizumab, an FDA-approved drug targeting inflammation, can improve symptoms like lack of pleasure and social withdrawal when added to current antipsychotic medications. Participants must have elevated anti-gliadin antibodies (AGA IgG), which are linked to increased inflammation. The trial aims to provide a targeted treatment for symptoms that standard therapies struggle to manage. Individuals with schizophrenia who have tested positive for AGA IgG antibodies may find this trial suitable. As a Phase 4 trial, it focuses on understanding how this already FDA-approved and effective treatment can benefit more patients.

You can continue taking your current antipsychotic medications, but you cannot take immunosuppressive or certain anti-inflammatory medications like NSAIDs or high-dose aspirin. If you use anti-inflammatory medications occasionally, that's allowed.

Research has shown that mirikizumab, the treatment under study in this trial, is generally well-tolerated. In one study involving patients with ulcerative colitis, 7.4% of those taking mirikizumab experienced serious side effects, which are important but not very common. Additionally, 5.3% of patients discontinued the treatment due to these side effects. Most reported side effects were mild. These findings suggest that while some risks exist, mirikizumab is generally safe for use in other conditions, indicating a positive safety profile for this trial.¹²³⁴⁵

Unlike the standard antipsychotics for schizophrenia, which typically target dopamine receptors, Mirikizumab offers a fresh approach by focusing on the IL-23 pathway. This is significant because IL-23 is linked to immune system regulation and inflammation, which recent research suggests might play a role in schizophrenia. Researchers are excited about Mirikizumab's potential to address untreated aspects of the disorder, possibly leading to a more comprehensive treatment with fewer side effects associated with current options.

This trial will compare the effects of mirikizumab, an IL-23 inhibitor, with a placebo in patients with schizophrenia. Studies have shown that mirikizumab, which blocks a specific protein involved in inflammation, effectively treats conditions with immune-related inflammation. In patients with ulcerative colitis, 24.2% of participants in a study experienced significant symptom relief by week 12. This suggests that mirikizumab can reduce inflammation and improve health outcomes. While primarily used for ulcerative colitis, it might also benefit a subgroup of schizophrenia patients with high inflammation levels. Early research indicates that targeting this immune pathway could offer new hope for treating symptoms like lack of motivation and thinking difficulties in these patients.¹²³⁶⁷